Shares of Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) have been battling to hold key support over recent days, with the stock testing and apparently holding the $1.75/share level on Thursday and Friday of last week. Adding to the narrative, the company just announced that it closed its prospectus sale to a single Canadian institutional accredited investor announced on December 3, 2018.
According to the release, “Pursuant to the Offering, the Company has issued 4,000,000 common shares of the Company at a price per Common Share of $2.70, for gross proceeds of $10.8 million. The Investor has an option to acquire up to a maximum of 1,555,555 additional Common Shares at a price per Common Share of $2.70 for a period of ten business days from the closing date. This Option was increased from the previously announced 600,000 Common Shares. Complete exercise of the Option would add gross proceeds of $4.2 million.”
Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) pulled in sales of $321K in its last reported quarterly financials, representing top line growth of 51.9%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($52.9M against $30.7M).
The company trumpets itself as a licensed producer of medical marijuana under the Access to Cannabis for Medical Purposes Regulations, which allows the company to produce and sell medical marijuana and cannabis oils to clients and other licensed producers.
Individuals may become clients of the company by registering with the company through its secure online portal or via telephone after the individual has received a medical document signed by a licensed health care practitioner setting out the daily quantity of dried marijuana, in grams, that the practitioner authorized for the person.
According to company materials, “Emerald Health Therapeutics Inc (OTCMKTS:EMHTF) operates through Emerald Health Botanicals Inc., a wholly owned subsidiary and Licensed Producer under the Access to Cannabis for Medical Purposes Regulations. Botanicals is authorized to produce and sell both dried medical cannabis flower and medical cannabis oil in Canada. Botanicals currently operates an indoor facility in Victoria, BC, and is progressing on expansion plans for a 32-acre property in Metro Vancouver and a partnership with Village Farms, called Pure Sunfarms, utilizing a 25-acre existing greenhouse complex in Delta, BC. Botanicals is one of Canada’s most medically focused licensed producers, with a team highly experienced in life sciences product development and large-scale agribusiness. Its vision is to be a leading provider of cannabis products through its production capabilities, proprietary genetics, value-added products and branding, and superb customer experience. Emerald Health Therapeutics is associated with the Emerald Health group, which comprises multiple companies advancing diverse botanical, nutraceutical and pharmaceutical products that may provide wellness and medical benefits by interacting with the body’s endocannabinoid system.”
Find out when $EMHTF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, EMHTF just announced that it closed its prospectus sale to a single Canadian institutional accredited investor announced on December 3, 2018. In all, we’ve witnessed -10% stripped out of share values of the stock over the past week of action.
Furthermore, the listing has registered increased average transaction volume recently, with the past month seeing 28% above the average volume levels in play in this stock over the longer term.
According to the release, “The Company intends to use the net proceeds of the Offering to fund the completion of capital projects, research and development, working capital, and general corporate purposes. The Common Shares were offered by way of a shelf prospectus supplement filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions and National Instrument 44-102 Shelf Distributions.”
Currently trading at a market capitalization of $294.19M, EMHTF has a significant war chest ($52.9M) of cash on the books, which compares with about $30.7M in total current liabilities. One should also note that debt has been growing over recent quarters. EMHTF is pulling in trailing 12-month revenues of $1.3M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 51.9%. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $EMHTF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $EMHTF, either long or short, and we have not been compensated for this article.